67 related articles for article (PubMed ID: 29391886)
1. Silencing of
Asai S; Miura N; Sawada Y; Noda T; Kikugawa T; Tanji N; Saika T
Oncol Lett; 2018 Jan; 15(1):522-527. PubMed ID: 29391886
[TBL] [Abstract][Full Text] [Related]
2. Ethylmalonyl-CoA decarboxylase, a new enzyme involved in metabolite proofreading.
Linster CL; Noël G; Stroobant V; Vertommen D; Vincent MF; Bommer GT; Veiga-da-Cunha M; Van Schaftingen E
J Biol Chem; 2011 Dec; 286(50):42992-3003. PubMed ID: 22016388
[TBL] [Abstract][Full Text] [Related]
3. The synthesis of branched-chain fatty acids is limited by enzymatic decarboxylation of ethyl- and methylmalonyl-CoA.
Dewulf JP; Gerin I; Rider MH; Veiga-da-Cunha M; Van Schaftingen E; Bommer GT
Biochem J; 2019 Aug; 476(16):2427-2447. PubMed ID: 31416829
[TBL] [Abstract][Full Text] [Related]
4. Variants in the ethylmalonyl-CoA decarboxylase (ECHDC1) gene: a novel player in ethylmalonic aciduria?
Fogh S; Dipace G; Bie A; Veiga-da-Cunha M; Hansen J; Kjeldsen M; Mosegaard S; Ribes A; Gregersen N; Aagaard L; Van Schaftingen E; Olsen RKJ
J Inherit Metab Dis; 2021 Sep; 44(5):1215-1225. PubMed ID: 33973257
[TBL] [Abstract][Full Text] [Related]
5. Blocking integrin β1 decreases adhesion in chemoresistant urothelial cancer cell lines.
Vallo S; Rutz J; Kautsch M; Winkelmann R; Michaelis M; Wezel F; Bartsch G; Haferkamp A; Rothweiler F; Blaheta RA; Cinatl J
Oncol Lett; 2017 Nov; 14(5):5513-5518. PubMed ID: 29113179
[TBL] [Abstract][Full Text] [Related]
6. A proteomic profiling of gemcitabine resistance in pancreatic cancer cell lines.
Mori-Iwamoto S; Kuramitsu Y; Ryozawa S; Taba K; Fujimoto M; Okita K; Nakamura K; Sakaida I
Mol Med Rep; 2008; 1(3):429-34. PubMed ID: 21479428
[TBL] [Abstract][Full Text] [Related]
7. Targeting metabolic reprogramming to overcome drug resistance in advanced bladder cancer: insights from gemcitabine- and cisplatin-resistant models.
Kawahara I; Yoshino H; Fukumoto W; Arima J; Saito S; Li G; Fukuda I; Mitsuke A; Sakaguchi T; Inoguchi S; Matsushita R; Nakagawa M; Tatarano S; Yamada Y; Enokida H
Mol Oncol; 2024 Jun; ():. PubMed ID: 38874588
[TBL] [Abstract][Full Text] [Related]
8. Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line Therapeutics.
Vallo S; Michaelis M; Rothweiler F; Bartsch G; Gust KM; Limbart DM; Rödel F; Wezel F; Haferkamp A; Cinatl J
Transl Oncol; 2015 Jun; 8(3):210-6. PubMed ID: 26055179
[TBL] [Abstract][Full Text] [Related]
9. Induction of drug-resistant bladder carcinoma cells in vitro: impact on polychemotherapy with cisplatin, methotrexate and vinblastine (CMV).
Rohde D; Brehmer B; Kapp T; Valdor M; Jakse G
Urol Res; 1998; 26(4):249-57. PubMed ID: 9759998
[TBL] [Abstract][Full Text] [Related]
10. Plant-Derived Sulforaphane Suppresses Growth and Proliferation of Drug-Sensitive and Drug-Resistant Bladder Cancer Cell Lines In Vitro.
Xie H; Rutz J; Maxeiner S; Grein T; Thomas A; Juengel E; Chun FK; Cinatl J; Haferkamp A; Tsaur I; Blaheta RA
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230603
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts.
Vallo S; Michaelis M; Gust KM; Black PC; Rothweiler F; Kvasnicka HM; Blaheta RA; Brandt MP; Wezel F; Haferkamp A; Cinatl J
BMC Res Notes; 2016 Sep; 9(1):454. PubMed ID: 27677700
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin resistance by induction of aldo-keto reductase family 1 member C2 in human bladder cancer cells.
Shirato A; Kikugawa T; Miura N; Tanji N; Takemori N; Higashiyama S; Yokoyama M
Oncol Lett; 2014 Mar; 7(3):674-678. PubMed ID: 24527071
[TBL] [Abstract][Full Text] [Related]
13. [Establishment and biological characteristics of a multi-drug resistant cell line A549/Gem.].
Wang W; Liu X; Liu G; Lin L; Zheng X; Zhu Y; Li X
Zhongguo Fei Ai Za Zhi; 2008 Feb; 11(1):55-61. PubMed ID: 20727268
[TBL] [Abstract][Full Text] [Related]
14. JAK-mediated autophagy regulates stemness and cell survival in cisplatin resistant bladder cancer cells.
Ojha R; Singh SK; Bhattacharyya S
Biochim Biophys Acta; 2016 Nov; 1860(11 Pt A):2484-2497. PubMed ID: 27474203
[TBL] [Abstract][Full Text] [Related]
15. NXPH4 Promotes Gemcitabine Resistance in Bladder Cancer by Enhancing Reactive Oxygen Species and Glycolysis Activation through Modulating NDUFA4L2.
Wang D; Zhang P; Liu Z; Xing' Y; Xiao Y
Cancers (Basel); 2022 Aug; 14(15):. PubMed ID: 35954445
[TBL] [Abstract][Full Text] [Related]
16. Drug-resistant human bladder-cancer cells are more sensitive to adenovirus-mediated wild-type p53 gene therapy compared to drug-sensitive cells.
Shirakawa T; Sasaki R; Gardner TA; Kao C; Zhang ZJ; Sugimura K; Matsuo M; Kamidono S; Gotoh A
Int J Cancer; 2001 Oct; 94(2):282-9. PubMed ID: 11668510
[TBL] [Abstract][Full Text] [Related]
17. Establishment and characterization of the gemcitabine-resistant human pancreatic cancer cell line SW1990/gemcitabine.
Yu Y; Ding F; Gao M; Jia YF; Ren L
Oncol Lett; 2019 Sep; 18(3):3065-3071. PubMed ID: 31452783
[TBL] [Abstract][Full Text] [Related]
18. PRPF19 functions in DNA damage repair and gemcitabine sensitivity via regulating DDB1 in bladder cancer cells.
Yu J; Ge S
Cytotechnology; 2024 Feb; 76(1):85-96. PubMed ID: 38304628
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor-β signaling induces cisplatin resistance in bladder cancer.
Goto T; Kashiwagi E; Jiang G; Nagata Y; Teramoto Y; Baras AS; Yamashita S; Ito A; Arai Y; Miyamoto H
Am J Cancer Res; 2020; 10(8):2523-2534. PubMed ID: 32905529
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of STAT signalling in bladder cancer by diindolylmethane: relevance to cell adhesion, migration and proliferation.
Sun Y; Cheng MK; Griffiths TR; Mellon JK; Kai B; Kriajevska M; Manson MM
Curr Cancer Drug Targets; 2013 Jan; 13(1):57-68. PubMed ID: 22920439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
